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El abordaje del tratamiento de una enfermedad tan compleja como el cáncer representa, en 
muchos aspectos, un gran desafío. A pesar de la enorme inversión en esfuerzo y capital en la 
investigación contra el cáncer en las últimas décadas, esta enfermedad continúa siendo hoy en 
día una de las principales causas de mortalidad en el mundo desarrollado. Y aún más, las 
previsiones indican que la incidencia de esta enfermedad continuará aumentando en el futuro, y 
particularmente en el caso del melanoma la tendencia indica una creciente prevalencia entre la 
población más joven (< 30 años).  
Las terapias tradicionales se han basado principalmente en la resección quirúrgica de los 
tumores, quimioterapia y radioterapia. No obstante, las principales limitaciones de estas terapias 
residen en la falta de universalidad en la respuesta de los pacientes y en la inducción de efectos 
secundarios nocivos. Por estos motivos, el desarrollo de nuevas terapias más específicas y 
eficaces sigue siendo aún un objetivo científico prioritario a nivel mundial. 
En este sentido, la inmunoterapia ha surgido como una alternativa prometedora en la lucha 
contra el cáncer. Desde el nacimiento de esta disciplina, en el siglo XIX, el interés en este campo 
se ha acrecentado exponencialmente a partir del año 2010. Los prometedores resultados 
obtenidos en ensayos clínicos han empujado a las agencias reguladoras de los medicamentos a la 
aprobación de diversos tratamientos basados en la inmunoterapia en los últimos años para su 
aplicación en clínica. 
Concretamente, la inmunoterapia se basa en el refuerzo de la respuesta natural del sistema 
inmune que es responsable de la búsqueda, detección y eliminación de las células cancerosas. En 
los primeros estadíos de la enfermedad, el propio organismo posee la capacidad de frenar el 
desarrollo del tumor, pero éste adquiere en etapas más avanzadas la capacidad de pasar 
desapercibido para el sistema inmune. Es por ello que, aunque de forma natural no es capaz de 
evitar la implantación y el desarrollo de un cáncer, el sistema inmune se convierte en una diana 
terapéutica clave. 
De manera particular, las células dendríticas se consideran la población celular más importante 
del sistema inmune, debido a que son las células presentadoras de antígeno más potentes, y a que 
enlazan de manera estratégica las dos principales ramas del sistema inmune: innata y adaptativa. 
Por una parte, son capaces de reconocer, capturar, procesar y presentar antígenos y de producir 
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citoquinas pro-inflamatorias en presencia de señales de peligro (o patrones moleculares 
asociados a patógenos, PAMPs por sus siglas en inglés). Por otra parte, tienen la habilidad de 
activar linfocitos T inmaduros tras la cross-presentación del antígeno, generando de esta manera 
potentes respuestas inmunitarias específicas de antígeno.  
Las estrategias de inmunoterapia basadas en células dendríticas exploradas hasta la fecha pueden 
clasificarse en dos grandes categorías: las llevadas a cabo in vivo y ex vivo. Las estrategias ex 
vivo se basan en el aislamiento de células dendríticas del paciente, seguido de una manipulación 
en el laboratorio consistente en la expansión de células dendríticas, la carga con antígenos y la 
inducción de su maduración. Finalmente, las células son re-inyectadas en el paciente una vez su 
potencial de acción ha sido reforzado. Por el contrario, a lo largo de este trabajo se ha tratado de 
desarrollar una estrategia de inmunoterapia orientada a inducir la activación y maduración de 
células dendríticas in vivo. Para ello, se ha desarrollado una vacuna basada en agentes 
inmunoestimuladores cuya diana es la población de células dendríticas. Una vez activada esta 
población celular, se espera un efecto amplificado que incluya respuestas celulares de tipo 
citotóxico, que finalmente eviten el crecimiento del tumor, y de tipo memoria para proporcionar 
una inmunidad duradera frente al cáncer.  
Dichos agentes inmunoestimuladores son agonistas de los receptores de tipo Toll (TLRs). Estos 
receptores se localizan en la membrana plasmática y en los endosomas de las células dendríticas 
(entre otras células del sistema inmune) y su función es la de reconocer PAMPs, entre los que se 
encuentran estructuras altamente conservadas a lo largo de la evolución como por ejemplo 
lípidos microbianos, carbohidratos, ácidos nucleicos o intermediarios de la replicación vírica. De 
esta manera, las células del sistema inmune pueden cumplir su función de centinelas frente a 
eventuales infecciones. Los agonistas de TLR elegidos son Poly(I:C) e imiquimod, dos 
moléculas sintéticas que activan, respectivamente, a los receptores TLR3 y TLR7. Se conoce que 
la combinación de diferentes ligandos de TLR provoca la activación y maduración de células 
dendríticas de manera sinérgica. Esto se traduce en la sobre-expresión de moléculas co-
estimuladoras como CD80 y CD86, la secreción de citoquinas pro-inflamatorias y quimioquinas 
que atraen células T naïve y memoria y el aumento de los niveles del receptor de quimioquinas 
C-C de tipo 7 (CCR7), que promueve la migración de células dendríticas desde los tejidos 
periféricos hasta los órganos linfáticos, donde residen la mayoría de las células inmunes, 
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facilitando así la amplificación de la respuesta inmune. De esta manera, se puede considerar a la 
combinación de agonistas de TLR como potentes adyuvantes que podrían potencialmente 
incorporarse como componentes de una vacuna junto con el antígeno tumoral modelo 
ovalbúmina. La activación de linfocitos T requiere de tres señales: la interacción del complejo 
MHC-antígeno con el TRC; la co-estimulación por parte de proteínas de superficie de las células 
presentadoras de antígeno, que proporcionarían una señal reguladora (activadora o inhibidora) de 
la activación de células T; y la secreción de citoquinas que determinan la polarización de las 
células T inmaduras hacia los diversos fenotipos de linfocitos T maduros que existen (CD4+, 
CD8+, Treg o Th17). La generación de potentes respuestas celulares CD8
+ específicas de antígeno 
son esenciales para la eliminación de las células tumorales, ya que esta población celular ejerce 
una acción citotóxica directa sobre células que son reconocidas como extrañas por el sistema 
inmune. De hecho, este tipo de respuestas son responsables de suprimir o retrasar el crecimiento 
de tumores in vivo en modelos animales experimentales vacunados siguiendo un esquema 
profiláctico y/o terapéutico.  
A pesar de los beneficios que podría potencialmente aportar la inmunoterapia, su éxito también 
se encuentra limitado por diversas razones. Fundamentalmente, la administración de agentes 
inmunoestimuladores debe ser dirigida hacia los órganos y la población celular diana, en este 
caso los órganos linfáticos y las células dendríticas, respectivamente, para evitar desencadenar 
una respuesta inflamatoria inespecífica a nivel sistémico. Por otra parte, tanto el antígeno como 
el adyuvante deberían alcanzar a las células diana simultáneamente para inducir su correcta 
activación. Además, la administración sistémica de los componentes de la vacuna puede diluir la 
eficacia del tratamiento con dos consecuencias: primero, se requerirían repetidas dosis para 
conseguir una concentración farmacológicamente activa, y por otra parte, la acumulación en el 
organismo de compuestos con actividad farmacológica en altas concentraciones podría conllevar 
efectos tóxicos.  
La nanotecnología ha surgido como un campo que ofrece aproximaciones prometedoras para 
complementar y potencialmente solventar las limitaciones a las que se enfrenta la inmunoterapia. 
El diseño de nanoparticulas permite controlar las propiedades que van a determinar su 
comportamiento dentro del organismo y por tanto, su aplicabilidad para el reconocimiento y 
eliminación de células cancerosas. Determinadas características de las nanoparticulas como el 
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tamaño, la carga, la forma, el material y las propiedades de superficie determinan su 
biodistribución, biocompatibilidad e inmunogenicidad, la capacidad de transportar y liberar 
compuestos terapéuticos de manera dirigida y controlada y la posibilidad de ser analizadas in 
vivo mediante técnicas de imagen molecular.  
En esta tesis se ha propuesto como estrategia inmunoterapéutica el diseño de una vacuna basada 
en nanoparticulas de óxido de hierro y biofuncionalizadas con una combinación sinérgica de 
agonistas de TLR y un antígeno tumoral modelo con el objetivo de ser dirigidas de manera 
específica hacia el sistema inmune y generar así una eficaz respuesta inmune antitumoral. 
Se conoce que el tamaño controlado de las nanoparticulas puede utilizarse como una estrategia 
de direccionamiento pasivo hacia los nódulos linfáticos. De esta manera, se potencia la 
inmunogenicidad del sistema mediante la liberación de compuestos immunoterapéuticos de 
forma dirigida a los órganos diana, evitando al mismo tiempo una posible toxicidad sistémica. 
Además, el empleo de sistemas agregados de un mayor tamaño también presenta una actividad 
inmunoestimuladora debido a la liberación sostenida de antígeno y adyuvante. La combinación 
de ambas estrategias podría, además, tener un efecto sinérgico. 
La propia composición de las nanoparticulas asegura una elevada biocompatibilidad. 
Especialmente tres de los componentes empleados en la formulación: el hierro, un metal que 
interviene de manera natural en diferentes procesos fisiológicos; el polietilenglicol, un lípido 
ampliamente empleado en la industria farmacéutica debido a su alta biocompatibilidad y 
biodegradabilidad y a su baja toxicidad; y el imiquimod, un agonista de TLR7 actualmente 
aprobado por las agencias reguladoras de los medicamentos para su empleo en clínica para el 
tratamiento de varios procesos neoplásicos.  
En cuanto a la interacción entre las nanovacunas y el sistema inmune, las nanoparticulas actúan 
como una plataforma para el co-transporte y liberación de antígeno y adyuvantes a una célula 
dendrítica diana y a un mismo compartimento celular, los endosomas, donde además se localizan 
los receptores TLR3 y TLR7. A su vez, durante el transporte los ligandos de TLR están 
protegidos por la nanoparticula frente a la degradación que pueden sufrir en su forma libre. 
Además, el transporte de antígeno y adyuvantes acoplados a una nanoparticula aumenta las 
probabilidades de que dichas biomoléculas sean endocitadas por las células presentadoras de 
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antígeno. La propia composición de la nanoparticula podría también actuar como un adjuvante 
per se. Concretamente, las nanoparticulas de óxido de hierro podrían desencadenar la 
polarización pro-inflamatoria del microambiente tumoral. El empleo de nanopartículas cargadas 
de compuestos bioactivos permite además la acumulación de dichas moléculas en una 
concentración biológicamente significativa de forma localizada, lo cual implica que las dosis 
requeridas para ejercer su acción son más bajas en comparación con la correspondiente forma 
libre, contribuyendo así a reducir la toxicidad asociada al tratamiento. En conjunto, estas 
características potencian el efecto del tratamiento con nanovacunas.  
En esta tesis se han evaluado dos tipos de nanoparticulas de óxido de hierro: con y sin la 
superficie dopada con zinc. El dopaje mejora las propiedades de las nanoparticulas como agentes 
de contraste. Esta cualidad hace de este tipo de nanoparticulas un potencial candidato para la 
combinación de un agente diagnóstico y terapéutico en una misma plataforma. No obstante, en el 
diseño que proponemos en este trabajo la diana principal es el sistema inmune más que el propio 
tumor. En cualquier caso, permite su seguimiento in vivo y por consiguiente el análisis de su 
biodistribución mediante imagen por resonancia magnética. Concluimos que la 
biofuncionalización de las nanoparticulas modifica su distribución in vivo, sin afectar 
negativamente las propiedades inmunoestimuladoras del sistema.  
El empleo de la combinación de ligandos de TLR Poly(I:C) e imiquimod como adyuvantes ha 
resultado ser extremadamente efectiva, hasta el punto de evitar el crecimiento de un modelo 
tumoral de melanoma durante varios meses tras la vacunación y subsiguiente inoculación del 
tumor. Además, la respuesta de memoria inmune generada es tan fuerte como para impedir el 
crecimiento del tumor tras una segunda inoculación. A pesar de la potencia de los adyuvantes, la 
nanoparticula contribuye acelerando y/o potenciando la generación de respuestas inmunes 
específicas de antígeno tanto de tipo celular como humoral.  
Especial mención merece la actividad de la nanovacuna como agente terapéutico. En 
comparación con el enfoque profiláctico, la eficacia es razonablemente más limitada puesto que 
el sistema inmune carece del tiempo necesario para desarrollar la habilidad de responder de 
manera adecuada a una señal de peligro. No obstante, en términos relativos, es capaz de inducir 
un retraso en el crecimiento tumoral comparable con el que se consigue mediante ciertos 
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tratamientos quimioterapéuticos. En cualquiera de los casos, queda demostrada la capacidad de 
la vacuna para retrasar o impedir el desarrollo tumoral, así como de prolongar la supervivencia.  
En definitiva, este trabajo pone en relieve la efectividad de una nueva vacuna basada en 
nanoparticulas como estrategia inmunoterapéutica aplicada al tratamiento del melanoma. Aporta 
como novedad el empleo simultáneo en la formulación de vacunas, por una parte, de 
nanoparticulas inorgánicas, y por otra parte, de una combinación sinérgica de ligandos de TLR, 
ambas estrategias aún poco exploradas. Por último, se sientan las bases para continuar 
explorando extensivamente nuevos y potentes adyuvantes aplicables a diferentes tipos de 
vacunas, así como la incorporación de nanomateriales para potenciar su efecto.  
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Tackling the treatment of such a complex disease as cancer represents, in many senses, a big 
challenge. In spite of the huge investment both in effort and money in cancer research during the 
last decades, this disease still remains being one of the main mortality causes in the developed 
countries. What is more, foresights point out that the incidence of this illness will continue rising 
in the future. In the particular case of melanoma, there is a tendency for increasing prevalence 
rates among the youngest population (< 30 years). 
Traditional therapies are mainly based on the surgical resection of tumors, chemotherapy and 
radiotherapy. Nevertheless, the main limitations of these treatments are the lack of universality in 
the patient’s response and the induction of harmful side effects. These are the reasons why the 
development of more specific and effective new therapies is nowadays a priority scientific goal 
worldwide.  
In this sense, immunotherapy has emerged as a promising alternative in the fight against cancer. 
Since the beginning of this field, in the 19th century, it has been gaining interest exponentially 
since 2010. The promising results obtained in clinical trials have encouraged the drug regulatory 
agencies to license different immunotherapy-based treatments in the last years for their clinical 
application.  
Immunotherapy aims the reinforcement of the natural response of the immune system 
responsible of seeking, detecting and eliminating cancer cells. During the first stages of the 
disease, the organism itself owns the ability to arrest tumors development, although they acquire 
in more advanced stages the capacity to avoid the immune recognition. For this reason, the 
immune system represents a key therapeutic target although it is frequently unable to avoid the 
implantation and development of a tumor by their means. 
Dendritic cells are considered to be the most important cellular population of the immune system 
since they are the most potent antigen presenting cells and strategically connect the two main 
immunological branches: innate and adaptive. On the one hand, they are able to recognize, 
capture, process and cross-present antigens and release pro-inflammatory cytokines in the 
presence of danger signals (pathogen associated molecular patterns, PAMPs). On the other hand, 
they are able to activate naïve T lymphocytes after the cross-presentation of the antigen, thus 
generating potent antigen-specific immune responses.  
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The dendritic cell-based immunotherapeutic strategies developed until the date can be classified 
into two classes: in vivo and ex vivo. Ex vivo approaches are based on the isolation of the 
patient’s dendritic cells followed by their expansion, antigen loading and maturation in vitro. 
Finally, cells are reinfused to the patient once their potential activity has been reinforced. By 
contrast, along this work we have attempted to develop an immunotherapeutic strategy guided to 
promote the activation and maturation of dendritic cells in vivo. With this purpose, we have 
developed a vaccine based on immunostimulatory agents whose target is the dendritic cell 
population. Once activated, we aim to elicit an amplified effect including cytotoxic cellular 
responses that ultimately avoid the tumor growth, as well as memory responses to provide a 
durable immunity against cancer.  
Such immunostimulatory agents are Toll-like receptors (TLRs) agonists. These receptors are 
located on the plasmatic membrane and endosomes of dendritic cells (among other immune 
cellular populations) and their role is the recognition of PAMPs. Some examples of PAMPs are 
certain structures highly evolutionarily conserved such as microbial lipids, carbohydrates, 
nucleic acids and mediators of viral replication. This way, the cells of the immune system act as 
sentinels against eventual infections. The selected TLR agonists are Poly(I:C) and imiquimod, 
two synthetic molecules that engage TLR3 and TLR7, respectively. It has been reported that the 
combination of different TLR agonists triggers the activation and maturation of dendritic cells in 
a synergistic manner. It involves the overexpression of co-stimulatory molecules such as CD80 
and CD86, the release of pro-inflammatory cytokines and chemokynes that attract naïve and 
memory T cells and the upregulation of the C-C chemokine receptor 7 (CCR7) that promotes the 
migration of dendritic cells from the peripheral tissues to the lymphatic organs, where most 
immune cells reside, thus enabling the amplification of the immune response.  
The combination of TLR agonists may be considered as a potent adjuvant which could 
potentially be incorporated as a vaccine component along with the tumoral model antigen 
ovalbumin. The activation of T lymphocytes requires three stimuli: the interaction between the 
complex MHC-antigen and the TCR; the co-stimulation by surface proteins of the antigen 
presenting cells, which provide a regulatory signal (positive or negative) for the activation of T 
cells; and the release of cytokines that determine the differentiation of immature T cells towards 
the diverse T lymphocyte phenotypes (CD4+, CD8+, Treg or Th17). The generation of potent 
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antigen-specific CD8+ cellular responses is essential for the eradication of tumors, since this 
cellular population exerts a direct cytotoxic activity on cells recognized by the immune system as 
strange ones. In fact, this kind of responses is responsible of the suppressed or delayed tumors 
growth in vivo in experimental animal models immunized following a prophylactic and/or 
therapeutic schedule.  
In spite of the potential benefits of immunotherapy, its success is limited due to different reasons. 
Importantly, the administration of immunostimulatory agents has to be guided to the target 
organs and cellular population (in this case the lymphatic organs and dendritic cells, 
respectively) in order to avoid a systemic unspecific inflammatory response. Furthermore, both 
the antigen and the adjuvant should reach the target cell simultaneously to induce a proper 
activation. Moreover, the systemic administration of the vaccine components may diminish the 
efficacy of the treatment with two consequences: first, repeated doses would be required to reach 
a pharmacologically active concentration and, on the other hand, the accumulation of high 
concentrations of compounds with pharmacologic activity inside the organism could result in 
toxic effects. 
Nanotechnology has emerged as a field that offers promising approaches to complement and 
potentially solve the limitations of immunotherapy. Nanoparticles engineering allows the fine 
tuning of the properties that determine their behavior inside the organism and so, their 
applicability for the recognition and elimination of tumor cells. Certain features of the 
nanoparticles, such as size, charge, shape, composition and surface properties determine their 
biodistribution, biocompatibility and immunogenicity, their ability to transport and deliver 
therapeutic compounds in a targeted and controlled manner as well as the possibility to be 
tracked in vivo through molecular imaging techniques.  
In this thesis, we propose as an immunotherapeutic strategy the design of a vaccine based on iron 
oxide nanoparticles biofunctionalized with a synergistic combination of TLR agonists and a 
model tumoral antigen to specifically target the immune system, thus generating an effective 
antitumoral immune response. 
It is known that the controlled size of nanoparticles can be used as a passive targeting strategy 
towards the lymph nodes. This way, the immunogenicity of the system is potentiated through the 
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release of immunotherapeutic drugs directly to the target organs, avoiding at the same time a 
possible systemic toxicity. Moreover, the employment of aggregated systems with a higher 
diameter also shows an immunostimulatory activity due to the sustained release of antigen and 
adjuvant. In addition, the combination of both strategies could have a synergistic effect.  
The nanoparticle composition ensures a high biocompatibility. Particularly, three of the 
compounds employed in the vaccine formulation: iron, a metal naturally involved in different 
physiologic processes; polyethylene glycol, a lipid commonly used in the pharmaceutical 
industry due to its high biocompatibility and biodegradability and its low toxicity; and 
imiquimod, a TLR7 agonist currently approved by the regulatory drugs agencies for its clinical 
application in the treatment of several neoplasic diseases. 
Regarding the interaction between the nanovaccines and the immune system, nanoparticles act as 
a platform for the simultaneous transport and co-delivery of antigen and adjuvant to a unique 
targeted dendritic cell and to the same intracellular compartment, the endosomes, where TLR3 
and TLR7 are located. Furthermore, TLR ligands are protected by the nanoparticle against the 
degradation they may undergo in their soluble forms during the transportation. Moreover, the 
attachment of antigen and adjuvants to a nanoparticle increases the probability for those 
biomolecules to be endocytosed by antigen presenting cells. The nanoparticle composition might 
act as an adjuvant per se. In particular, iron oxide nanoparticles can induce the pro-inflammatory 
polarization of the tumor microenvironment. The employment of nanoparticles loaded with 
bioactive compounds also enables the accumulation of such molecules in a biologically 
significant concentration in a localized manner, meaning that the doses required to exert their 
action are lower than those required by the soluble counterparts, thus contributing to reduce the 
toxicity associated to the treatment. Altogether, these characteristics boost the effect of the 
nanoparticle-based treatments. 
In this thesis we have evaluated two kinds of iron oxide nanoparticles: with and without a zinc-
doped surface. The doping improves the properties of the nanoparticles as contrast agents. This 
feature makes them a potential candidate for the combination of a diagnostic and a therapeutic 
agent on the same platform. Nevertheless, the main target we propose is the immune system 
rather than the tumor. In any case, it is a characteristic that enables their tracking in vivo and, 
consequently, the analysis of their biodistribution through magnetic resonance imaging. We 
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conclude that the biofunctionalization modifies nanoparticles in vivo distribution, without 
adversely affecting the immunostimulatory properties of the system. 
The combination of TLR agonists Poly(I:C) and imiquimod as vaccine adjuvants has turned to be 
extremely effective, to the point of avoiding the development of a melanoma tumor model for 
several months after the immunization and subsequent tumor inoculation. Moreover, the memory 
immune response generated is strong enough as to inhibit tumor growth after a second challenge. 
Despite the potency of the adjuvants, the nanoparticle contributes accelerating and/or 
potentiating the onset of both cellular and humoral antigen-specific immune responses. 
The activity of the nanovaccine as a therapeutic agent deserves a special mention. Compared to 
the prophylactic approach, the efficacy is reasonably more limited as the immune system lacks 
the time necessary for developing the ability to respond appropriately against a danger signal. 
Nevertheless, in relative terms, it is able to induce a delayed tumor growth similar to the one 
achieved through certain chemotherapeutic treatments. In any case, the ability of the vaccine to 
the delay or avoid the tumor development and to extend mice survival has been demonstrated.  
Definitely, this work highlights the effectiveness of a new nanoparticle-based vaccine as an 
immunotherapeutic strategy applied to the treatment of melanoma. As a novelty, it combines on 
the same vaccine formulation inorganic nanoparticles, on the one hand, and a synergistic 
combination of TLR agonists on the other hand, both strategies scarcely explored until the date. 
Finally, it opens an avenue for a deeper assessment of new and potent adjuvants applicable to 
different kinds of vaccines, as well as the incorporation of nanomaterials to boost their effect.
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This initial chapter aims to contextualize and provide the general background 
of this PhD thesis and the research project carried out. It provides a brief overview 
of the fields of cancer immunotherapy and cancer nanomedicine, and describes and 
discusses the state-of-the-art, challenges and opportunities in the development of 
nanoparticle-based anti-cancer vaccines. 
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1.1. Immunotherapy. 
 
1.1.1. Definition and history. 
The term immunotherapy refers to the reinforcement of the host immune system in order to 
trigger an endogenous anti-tumor response. In the earliest stages of the neoplastic process, 
mutated proteins, known as ‘neoantigens’, are generated and presented on the surface of tumor 
cells. These antigens are recognized by professional antigen presenting cells (APCs) and cross-
presented to T lymphocytes. The interaction between the TCR of T-cells and the complex MHC-
antigen of APCs, together with additional co-activation signals, ultimately leads to the activation 
of an anti-tumor immune response. In this way, the host immune system can avoid the 
development of cancer during the early stages. Nevertheless, the tumor develops distinct 
resistance mechanisms in order to escape from the immune surveillance and destruction. The 
most relevant mechanisms are the establishment of a strong immunosuppressive tumor 
microenvironment, the inhibition of T-cells activity and the progressive generation of poorly 
immunogenic and/or apoptosis-resistant tumor cells. These tumor-escape mechanisms have 
compromised the efficacy of immunotherapeutic strategies.  
The birth of immunotherapy dates back to the 19th century, when William B. Coley successfully 
triggered an anti-tumor immune response against sarcoma after the local administration of 
bacteria-derived toxins into the patients. Since then, several attempts have aimed to stimulate 
immune-related responses to fight against cancer. For instance, the injection of cytokines such as 
IL-2 or IFNα has been applied in cancer treatment for several decades. However, recent 
advances since 2010 are giving back immunotherapy the deserved relevance 1: the approval by 
the FDA of the first autologous cellular immunotherapy, sipuleucel-T, for the treatment of 
prostate cancer in 2010; the approval of anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab) 
antibodies in 2011 and 2014 respectively; and the combination of both antibodies for the 
treatment of melanoma in 2015. 
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1.1.2. Immunotherapeutic strategies. 
Before defining the place of this thesis in the vast immunotherapy field, a general overview of 
the different cancer immunotherapy approaches will be given 2–4: 
- Strategies to activate effector T-cell responses. 
o Vaccination with neoantigens.  
It consists on the administration of tumor associated antigens (TAAs), either in 
the form of full-length recombinant proteins, synthetic peptides, whole tumor 
cells or tumor cell lysates. The most important and challenging issue is the 
isolation of the most appropriate antigen or, alternatively, the supply of an antigen 
source which provide the most varied epitope profile possible. GVAX, the most 
promising approach currently under development, is a vaccine consistent on an 
entire tumor cell as a source of antigens, genetically modified to release the 
cytokine GM-CSF and irradiated to avoid further proliferation 5. 
o Vaccination with antigen plus adjuvant. 
The main limitation of a vaccine composed solely by antigens is the inadequate 
activation of dendritic cells (DCs). This cellular population plays a key role in the 
coordination of innate and adaptive immune responses. Therefore, their activation 
and maturation is essential in order to trigger potent responses that overcome the 
ability of the tumor to induce immune tolerance. To do so, several strategies have 
been designed based on the activation of innate immune signaling pathways 
involved in the activation of DCs through the release of interferons (IFN) and 
other pro-inflammatory cytokines as well as through the overexpression of several 
co-stimulatory signals. As an example, the employment of Toll-Like Receptors 
(TLR) and Stimulator of Interferon Genes (STING) agonists is an available 
strategy to trigger innate mechanisms of defense against pathogens since those 
molecules show a potent adjuvanticity that reinforces the effect of the vaccines 6, 
7. 
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o Virotherapy. 
It is based on the use of natural or genetically engineered viruses that selectively 
infect and ultimately cause lysis of tumor cells with minimal disturbance of 
normal cells. Apart from the direct oncolytic activity, the virus-induced cell death 
releases virus progeny, Pathogen Associated Molecular Patterns (PAMPs), 
Damage Associated Molecular Patterns (DAMPs) and Tumor-Associated 
Antigens (TAAs) that trigger a systemic anti-tumor response. To date, only one 
virotherapy drug has been approved by the FDA and the EMA for the treatment of 
advanced melanoma, Talimogene laherparepvec (T-VEC) 8, 9. 
 
- Strategies to neutralize immunosuppressor mechanisms. 
o Immune checkpoint blockade. 
Immune checkpoints are inhibitory receptors whose activation impedes T-cell 
function 10. Their physiological role is to balance the magnitude of immune 
responses to avoid damage to the own tissues, as well as to avoid reactivity to 
self-antigens. However, tumors employ immune checkpoints as a mechanism of 
immune evasion. Then checkpoint blockade, understood as the blockade of 
immune inhibitory pathways activated by tumor cells, is being used as a 
successful therapeutic strategy. To date, five monoclonal antibodies have been 
approved by the FDA for their clinical use: anti-CTLA-4 (Ipilimumab), anti-PD-1 
(Nivolumab and Pembrolizumab) and anti-PD-L1 (Atezolizumab and 
Durvalumab) antibodies 11, 12. 
o Alternative checkpoint inhibitors. 
Several alternative immune checkpoints are currently under investigation for 
potential use in advanced cancer. Two of them, Lymphocyte Activation Gene 3 
(LAG3) and T cell Immunoglobulin 3 (TIM3), are proteins expressed on the 
surface of exhausted T cells. Their inhibition might overcome T cell anergy, 
leading to oncolytic responses. Killer immunoglobulin-like receptors (KIRs) are 
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immune checkpoints of NK cells that have also gained attention because their 
blockade prevents the recognition of HLA molecules, thus triggering the 
destruction of tumor cells by NKs in an antigen-independent manner 13.  
o Inhibition of immunosuppressive tumor microenvironment. 
The enzyme indoleamine 2, 3-dioxygenase (IDO) is involved in the maintenance 
of the immunosuppressive tumor microenviroment through Treg activation and 
CD8+ T cells inhibition. Therefore, the targeted blockade of IDO is an interesting 
therapeutic approach currently under development.  
 
- Supply of agonists of co-stimulatory signals. 
The alternative to the blockade of inhibitory signaling pathways in T cells is the 
activation of co-stimulatory receptors, such as CD137, OX40, CD40 or GITR. In this 
case, monoclonal antibodies have been designed and applied as selective agonists of such 
receptors, thus triggering anti-tumor cellular responses.  
 
- Cell-based therapies. 
o Tumor-infiltrating lymphocytes (TILS). 
CTLs and Th cells are isolated from the tumor and cultured ex vivo in order to 
expand tumor antigen-specific cellular populations that are physiologically 
repressed in the tumor microenvironment. After a chemotherapy or radiotherapy-
based lymphodepletion that aim the destruction of immunosuppressive cellular 
populations in the tumor such as Treg or MDSCs, activated TILs are reinfused 
back to the patient, resulting in the tumor rejection 14.  
o DC-based vaccines. 
This therapy is based on the extraction of DCs from the patient’s peripheral blood, 
followed by their activation and antigen loading ex vivo and the subsequent 
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readministration to the patient. The first adoptive cell therapy approved, 
Sipuleucel-T, is based on DCs and is applied to prostate cancer treatment. In this 
case, this cellular population is genetically modified to express a prostate cancer 
antigen and a recombinant protein which encodes a prostatic acid phosphatase and 
the cytokine GM-CSF 15.  
o TCR transfer. 
This approach involves the genetic engineering of T-cells to express the α and β 
chains of the T cell receptor (TCR), which confers them the ability to specifically 
recognize neoantigens presented by tumors through the HLA/MHC complex 16. 
o Chimeric antigen receptor therapy (CART). 
It is a variation of the latter strategy that overcomes its main limitation: the down-
regulated expression of HLA by tumor cells as an immune evasion mechanism. 
Chimeric antigen receptors are constituted by an Ig variable domain fused to a 
TCR constant domain. The fragment of the protein derived from the variable 
chains of an antibody ensures the recognition of neoantigens with a high 
specificity in a HLA-independent manner 17–19. Kymriah® (tisagenlecleucel), the 
first CART-based therapy approved by the FDA, was recently licensed (in August 
of 2017) for the treatment of a pediatric form of acute lymphoblastic leukemia 20. 
It is a genetically-modified autologous T cell immunotherapy, by which the 
patient’s T cells are isolated and genetically modified to insert a new gene that 
codifies a specific protein (a chimeric antigen receptor or CAR) that directs T 
cells against leukemia cells that show a particular antigen (CD19) on the surface. 
Once modified, T-cells are reinfused back to the patient. 
 
1.1.3. Vaccines: state-of-the-art, current limitations and future prospects. 
Our position in the promising and challenging immunotherapy field is the anti-cancer vaccine 
approach. The strategy proposed in this thesis is based on the co-delivery of an antigen and a 
synergistic combination of TLR agonists as adjuvants using inorganic nanoparticles as delivery 
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platforms applied to the treatment of a melanoma tumoral model.  
In general, there are two types of anti-cancer vaccines: prophylactic (or preventive) and 
therapeutic (or healing) vaccines, depending on whether their administration is prescribed before 
or after the appearance of the malignancies, respectively.  Prophylactic vaccines aim to develop 
immunological memory in healthy subjects to prevent the appearance of a disease. Certain 
chronic viral infections, such as human papillomavirus (HPV), hepatitis B and C viruses (HBV 
and HCV), Epstein-Barr virus (EBV) and Helicobacter pilori, are related to carcinogenesis. To 
date, only three prophylactic vaccines against virus-related carcinomas have been approved by 
the FDA: Gardasil® and Cervarix® for the prevention of cervical cancer (HPV) and Fendrix® 
against liver cancers resulting from the sustained infection of the hepatitis B virus 21.  
Conversely, therapeutic vaccines aim to raise an immune response against an ongoing disease. In 
the case of cancer, the goal is to arrest tumor growth and prevent subsequent relapses. Apart 
from the FDA-approved Sipuleucel-T, Kymriah, T-VEC, anti-CTLA-4 and anti-PD-1 
monoclonal antibodies previously mentioned, several immunotherapeutic strategies are currently 
undergoing pre-clinical or clinical trials 22. Several examples of anti-cancer vaccines in the same 
line of our research can be found on databases about clinical trials. For instance, a variety of 
HER-2 derived synthetic peptides were administered in combination with Hiltonol, a variant of 
the TLR3 agonist Poly(I:C) with improved stability, to breast cancer patients in a clinical trial 
that was terminated with irrelevant immune responses to the vaccine 23. Applied to lung cancer, 
Tecemotide, which is a liposomal vaccine composed by a synthetic MUC-1 derived peptide 
adjuvanted with the TLR4 agonist MPLA 24, demonstrated in a phase III clinical trial a clinical 
benefit in terms of improved survival to patients that received simultaneously chemotherapy and 
radiotherapy prior to the immunization 25. The two TLR agonists used in this thesis, Poly(I:C) 
(TLR3) and imiquimod (TLR7), are currently being used separately in different clinical trials, 
but the combination of both TLR agonists, as well as any other TLR combination, still remains 
unexplored outside pre-clinical context. The use of imiquimod by itself for the treatment of viral 
external genital lesions (HPV papillomas), genital and perianal warts, superficial basal cell 
carcinoma and actinic keratoses was approved by the FDA in 2004 and is clinically used 
nowadays 26. Iron oxide nanoparticles (ferumoxytol, Feraheme®) are in turn being used and 
investigated in the context of magnetic resonance imaging (MRI), but not as components of 
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immunotherapeutic vaccines. Several authors have reported the successful application of 
nanoparticles loaded with a combination of TLR agonists for the induction of effective antigen-
specific cellular responses, improved pro-inflammatory cytokine release profiles and stronger 
antibody-mediated responses 27–30. The same approach was analyzed in the context of anti-cancer 
vaccines by Kornbluth et al 31 and Florindo et al 32, who demonstrated a significant B16F10 
tumor growth delay and improved survival in immunized mice. However, the development of 
magnetic nanoparticle-based multicarriers of TLR agonists as anti-cancer vaccine adjuvants still 
remains completely unexplored.  
Anti-cancer vaccines face several obstacles that hinder the development of successful treatments. 
An important issue is the immune-related toxicity. The therapeutic exacerbation of T-cell 
responses as well as the disruption of mechanisms that balance the magnitude of immune 
responses leads to the proliferation of immune cellular populations whose physiological role is 
the immune suppression, such as Treg and MDSCs. This could eventually lead to an accelerated 
tumor growth or to the transient inhibition of endogenous anti-tumor responses 33. Nevertheless, 
the undesirable side effects inherent to any treatment only limit its applicability when the degree 
of severity of the clinical symptoms is considered unacceptable. 
However, one of the main and most challenging obstacles is in the identification of the most 
appropriate antigen(s) to drive immune responses specifically against the tumor. In general, 
tumor cells show a poor antigenicity due to the down-modulated expression of MHC complexes, 
which is one of the mechanisms of tumor escape from immune surveillance. Apart from that, 
they show a heterogeneous antigen expression as a result of the antigenic variations generated by 
the process called ‘cancer immunoediting’, which avoids the implementation of universal 
strategies. Finally, most tumor antigens are self-proteins, therefore they would be accepted 
(tolerated) by the host immune system  as self-antigens. Three problems that point out to the 
crucial importance of identifying tumor-associated antigens (TAAs) that are recognized by the 
immune system as strange and aberrant proteins. Several TAAs have been identified resulting 
from mutations in oncogenes or oncosuppressor genes (e.g. BRCA1, BRCA2, HER2), 
developmental antigens (e.g. MAGE, melan-A, gp100), antigens upregulated during malignant 
transformation (e.g. CEA) and viral antigens associated with oncogenesis 21. Different 
approaches have been assessed in order to tackle the problem of antigen choice. First, the 
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administration of whole tumor cells or tumor cell lysates provides a wide variety of tumoral 
antigens. Despite being an excellent antigenic source, this strategy still needs to solve problems 
related to safety and self-reactogenicity. Subunit vaccines have emerged as a promising 
alternative since synthetic peptides can be inexpensively produced at large scale, easily 
administered to patients and allow monitoring antigen-specific immune responses 21. To face the 
problem of antigen heterogeneity, polyvalent vaccines provide several of the most frequent 
epitopes of the TAAs related to a particular type of cancer, thus increasing their effectiveness. 
They can be constituted by full length proteins or a pool of antigenic peptides. Monovalent 
vaccines that contain only one antigen with narrow epitope specificity correlate with low success 
rates in clinical trials 22. Nevertheless, some authors report that the immunization with a unique 
antigen might lead to the onset of immune responses against other TAAs 34. While the 
convenience of using a single antigen is not clear yet, the necessity of incorporating one or 
several adjuvants to the vaccine formulation is widely accepted, since synthetic purified antigens 
are poorly immunogenic.  
Other parameters that limit the development of effective anti-cancer vaccines are related to the 
optimization of the schedule, dosing and route of administration of the vaccine, the choice of 
suitable adjuvants and delivery vehicles and the optimal strategy to induce the activation and 
maturation of DCs. 
Current trends in research that define the future development of vaccines are related to different 
topics 22, 33: 
- The employment of delivery platforms that possess inherent immunogenic properties 
such as viral vectors, liposomes or pathogen-like micro- or nanoparticles. 
- The discovery of new potent adjuvants that preferentially activate Th1 and CTL 
responses. 
- Development of immunotherapeutic strategies in the context of multimodal treatments 
that combine tumor surgical resection, chemotherapy, radiotherapy and immunotherapy 
with potential synergistic mechanisms of action. 
- Definition of predictive biomarkers that enables the selection of patients with a higher 
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probability of developing a successful response to a particular treatment. This would 
allow the clinicians to decide the most appropriate treatment strategy in a personalized 
manner.  
 
1.2. Nanoparticles in nanomedicine and for the development of nanovaccines in cancer 
immunotherapy. 
Magnetic nanoparticles are already used for a variety of applications in nanomedicine 35, 36: 
o Controlled magnetic transport and immobilization of cells and biological 
materials. The magnetic properties of iron oxide nanoparticles are useful for 
tagging biological materials of interest, as well as living cells, and subsequently 
immobilizing or moving them towards the region of interest using a magnetic 
field gradient 37. This application has also an interest for the isolation of 
concentrated samples for further manipulation or analysis ex vivo 38–40. 
o Targeted drug delivery. Related to the previous application, in this case the 
magnetic nanocarriers provide targeted delivery of chemotherapeutic drugs or 
diagnostic radioactive probes to a particular region within the body, such as a 
tumor, taking advantage of the penetrability of magnetic fields into mammals’ 
tissues and avoiding undesirable off-targeted side effects 41, 42. Magnetofection is 
the delivery of genetic material inside target cells for gene therapy based on the 
same principles. 
o Hyperthermia treatments. Nanoparticles are directed to the cancerous tissue and 
exposed to a magnetic field with a strength and frequency enough as to generate 
heat. Tumor cells exposed to a high temperature (> 40 °C) for a long time (> 30 
min) are destroyed 43, 44. 
o Magnetic resonance imaging (MRI) contrast enhancement. Iron oxide 
nanoparticles provide excellent contrast agents for MRI for several reasons: high 
biocompatibility and differential uptake for different tissues (preferentially liver 
and reticuloendotelial system) in a size-dependent manner. They can also act as 
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multimodal imaging devices and as labels for in vitro and in vivo cellular tracking 
45–48.  
1.2.1. Advantages of particulate vaccines. 
The use of cytokines and TLR agonists (TLRa) to induce the activation and maturation of DCs 
avoids the disadvantages of DC-based vaccines, which as an adoptive cell therapy requires the 
isolation and manipulation DCs ex vivo, and therefore presents safety issues, is time consuming 
and expensive. Nevertheless, apart from the aforementioned obstacles to the development of 
successful anti-cancer vaccines (immunosuppressive tumor microenvironment, potential toxicity, 
poor antigenicity), the clinical success of these vaccines is restricted partly due to the toxicity 
associated to the systemic release of TLR agonists and the reduced effectiveness of a non-
targeted delivery to DCs. This hurdle can potentially be overcome by the use of particle-based 
delivery vehicles. The development of particulate vaccines provides a range of advantages: 
 The controlled release of the vaccine components to the target cells allows the 
employment of low dosages that reduce potential toxic side-effects. The local 
concentration reached at the target organs is significantly higher for nanoparticulate drugs 
than with the same drugs in solution 49.  
 Certain parameters enable the reduction of antigen and adjuvant quantities required to 
exert an immunological effect. Parameters that can be optimized to improve the efficacy 
and safety of the vaccine include the nanoparticle size and composition, the surface 
modification with ligands that target DCs and the addition of capping ligands that modify 
the biodistribution of nanoparticles or facilitate their drainage and/or retention into the 
lymphatic system 50. 
 The high surface-area-to-volume ratio allows the attachment of a variety of ligands and 
drugs 51. 
 The attachment of antigen and adjuvants to nanocarriers protects them from proteasomal 
degradation 29. 
 The delivery of TLRa on nanoparticles improve their safety profile, allow the use of 
potent adjuvant combinations and enable the employment as adjuvants of small 
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molecules with poor pharmacokinetics 52. 
 APCs efficiently internalize nanoparticles both through passive and active targeting. 
Consequently, even non-targeted nanoparticles enhance the uptake of the ligands they 
carry compared to their soluble forms. 
 Nanoparticles allow the simultaneous intracellular presence of both antigen and adjuvant, 
boosting the efficacy of the treatment and mediating the polarization of the immune 
responses elicited. 
 
As a strategy, targeting the immune system instead of directly attacking tumor cells is more 
effective for several reasons 51. First, whereas guiding nanoparticles to the tumor after a systemic 
administration is rather challenging, it is possible to accumulate them in lymphoid organs, where 
most APCs are located, both through passive and active targeting 53, 54. It has been estimated that 
only 0.7 - 0.9 % of the total nanoparticle dose injected ultimately reaches the tumor 55 in spite of 
the contribution of active tumor targeting strategies such as the coupling to nanoparticles of 
ligands such as aptamers, transferrin, folic acid, EGFR ligands or integrin-binding peptides and 
the employment of anti-HER2 and anti-VEGF monoclonal antibodies 56, 57. Second, lymphoid 
organs (particularly the spleen) are more permeable structures than tumors due to the lack of the 
physical barriers characteristic of solid tumors, such as a high interstitial pressure or a high-
density extracellular matrix 51. Although nanoparticles may penetrate the tumors through passive 
diffusion and accumulate inside them as a result of the leaky vasculature in the tumor tissue and 
a poor lymphatic drainage (the so called enhanced permeability and retention (EPR) effect), the 
reticuloendothelial and renal systems compete with the tumor for circulating nanoparticles and 
sequester or eliminate up to 99% of them 58, 55. Third, the magnitude of the immune responses is 
highly amplifiable. It means that while tumor cells require to be exposed to high doses of 
oncolytic drugs to be killed, even a low quantity of an immostimulating agent may trigger the 
onset of a strong anti-cancer immune response 50. In terms of designing a therapeutic nanocarrier, 
it is quite relevant as the amount of ligands to be loaded on the nanoparticle is much higher in the 
case of chemotherapeutic agents. Fourth, the generation of a memory response to prevent 
subsequent relapses is only possible for immunotherapies. Finally, in the majority of 
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nanoparticle-based therapeutic approaches, the immune system is an obstacle since the 
phagocytes of the reticuloendothelial system rapidly remove nanoparticles from the systemic 
circulation, thus hindering their action 59.  
 
1.2.2. Engineering nanoparticle-based vaccines: state-of-the-art, current limitations and 
future prospects. 
Engineering of nanoparticle-based vaccines relies on the cooperation between materials science 
and immunology. The design of immunoactive biomaterials requires a deep understanding of the 
physicochemical properties of the materials and the general functioning of the immune system in 
order to elucidate issues such as the host-material interactions or the spatiotemporal distribution 
of nanoparticles, antigen and adjuvants, as well as the biological responses they elicit. 
Nanoparticles have sizes in the range of different biological entities such as viruses (10-200 nm) 
or proteins (2-15 nm) 60. Several kinds of nanoparticles are being used for the development of 
vaccines (Table 1.1). These nanoparticles can be engineered to resemble pathogen-mimetic 
structures such as immune protein complexes, viruses or bacteria (Figure 1.1).  
 
 
Table 1.1. Classification of nanoparticles used in nanovaccines according to their composition. 
Taken from Bachmann et al 61. 
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Figure 1.1. Biomaterial-base vaccines engineered to resemble naturally occurring pathogens. 
Taken from Irvine et al 52. 
 
For example, antigenic molecules (usually peptides) and adjuvants such as PAMPs can be 
associated to nanomaterials in different ways 62, 63. In general, the interaction of biomolecules 
with nanoparticles can be classified in the following way: chemical conjugation to the 
nanoparticle surface; encapsulation inside nanospheres; adsorption to the surface through non-
covalent interactions; and simple mixtures of biomolecules and biomaterials. Adopting one of 
these strategies, or a combination of several of them, it is possible to develop pathogen 
mimicking structures. For instance, virus-like particles (VLPs) which are constituted by a self-
assembled proteic nanoparticle (20-100 nm in size) resembling a virus capsid and selected 
antigenic proteins conjugated to the surface have been used for decades in vaccines such as those 
against hepatitis B (HBV) and human papillomavirus (HPV). Other approaches are currently 
under investigation. As an example, Fahmy et al proposed a biomimetic nanoparticle (around 
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300 nm in diameter) made of the biodegradable polymer PLGA and functionalized with MPLA, 
CpG and OVA resembling the bacterial cell wall, the pathogen genome and an intracellular 
antigenic protein, respectively 29. Remarkably, the only kind of nanoparticle licensed as a human 
vaccine to date are VLP-based vaccines. Apart from Fendrix®, Gardasil® and Cervarix® (in use 
since the early 1980s, 2006 and 2007, respectively), a fourth VLP-based vaccine against hepatitis 
E was licensed in China in 2011 61. Based on the promising results obtained in advanced clinical 
trials, in 2015 the European Medicines Agency (EMA) adopted a positive scientific opinion 
about the anti-malaria vaccine candidate developed by GlaxoSmithKline under the trade name of 
Mosquirix® 64. Pilot implementation of this vaccine is expected to start in the coming years. 
Apart from VLP-based vaccines, only two other nanomedicines are currently approved: Doxil, a 
liposomal formulation of doxorubicin, and Abraxane, an albumin-bound nanoparticle of 
paclitaxel 49. Overall, it is reasonable to state that despite a number of successes the 
implementation of nanoparticle-based therapies is still in its early days.  
The ways by which a pathogen-like nanoparticle interacts with the host immune system to trigger 
an antigen-specific immune response are diverse 60,61,65,66 and all can be useful for nanoparticle-
based vaccine engineering (Figure 1.2). First, nanoparticles improve antigen uptake by 
professional antigen-presenting cells (APCs) compared to the soluble forms or microparticles. 
This strategy is likely to be the most effective one in terms of activation of effector cellular 
responses. The particle size also determines the migration of antigen-loaded nanoparticles from 
the periphery to the lymphatic system, enabling the co-delivery of antigen and adjuvants to 
relevant cellular populations. In general, nanoparticles of < 2 nm in diameter can penetrate blood 
vessels, whereas the optimal size to spontaneously reach the draining lymph nodes is around 10-
50 nm 52. Larger nanoparticles can also directly diffuse to lymphatic organs with a diminished 
rate or indirectly through peripheral circulating macrophages, which facilitate their transport to 
DCs 54. 
Large particles or nanoemulsions are retained at the site of injection, acting as biomaterial 
scaffolds that attract APCs to a matrix containing immunogenic material rather than as delivery 
vehicles that transport that material to the target cells 60. This phenomenon, known as ‘depot 
effect’, enables a sustained and prolonged antigen release. Furthermore, the pro-inflammatory 
activity of this approach is also related to the local release of cytokines and chemokines, the 
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recruitment of immune cellular populations and the up-regulated expression of CC-chemokine 
receptor 7 (CCR7) in DCs, which mediate their translocation to the draining lymphoid organs. 
 
 
 
Figure 1.2. Schematic representation of different strategies followed by nanoparticle-based 
vaccines in order to interact with the host immune system and shape the desired immune 
responses. Taken from Smith et al 60. 
 
Another approach commonly employed in the design of immunoactive nanoparticles is the 
incorporation of natural or synthetic PAMPs as adjuvants in addition to the antigen of interest. 
Nanoparticles deliver adjuvants into endosomal compartments of APCs, where important pattern 
recognition receptors (PRRs) are located. In this way, the nanoparticles are biomimetic structures 
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that mediate the activation of innate immune receptors, potentiating the immune responses 
triggered against the vaccine antigen. Next, antigen-presenting cells process and cross-present 
antigens to CD8+ T lymphocytes through the MHC-I complex, activating adaptive immune 
responses. Particulate carriers increase the chances of antigens to be cross-presented compared to 
their soluble forms due to the targeted delivery to the lymph nodes and enhanced nanoparticle 
uptake by APCs. Moreover, the possibility of co-delivering antigen plus adjuvant to a unique cell 
enables the reduction of the doses required to elicit effective immune responses.  
Finally, some materials show inherent adjuvanticity. For example, polymeric nanoparticles that 
contain a hydrophobic domain, such as those made of PLGA or chitosan, trigger the activation of 
dendritic cells in vitro and cellular responses in vivo even in the absence of additional adjuvants 
67. Iron oxide nanoparticles have recently been reported to induce a shift in the tumor 
microenvironment through the polarization of tumor associated macrophages (TAMs) from the 
M2 immunosuppressive to the M1 pro-inflammatory phenotype 68. The self-adjuvanticity of 
cationic liposomes remains controversial. Some authors support the activation of DCs as a 
consequence of the surface charge density associated to cationic nanoparticles 69, while others 
demonstrate the immunogenicity of neutral or anionic particles 70.  
From the biological point of view, nanoparticle-based immunotherapeutic strategies aim two 
main goals: the modulation of anti-tumor immunity and the regulation of the tumor 
microenvironment. In the first case, the objective is the generation of robust antigen-specific 
CTL responses to effectively recognize and eliminate tumoral cells. To tackle this, the activation 
of DCs has been demonstrated through a variety of strategies: 
- The coupling of antigens to nanoparticles, both entrapped 71 or chemically conjugated to 
them 72. The success of this strategy is based on the enhanced protection of the antigen on 
its way towards APC recognition. However, each approach (entrapment vs chemical 
conjugation) provides specific advantages. For instance, antigens packaged inside 
polymeric nanoparticles tend to present antigens to MHC-II, triggering CD4+ responses, 
whereas CD8+ T cell responses are preferentially activated upon the presentation of 
antigens to MHC-I by nanoparticles that carry the antigen attached to its surface 73. In this 
sense, the conjugation of antigen to nanoparticles would be preferable for the 
development of anti-cancer vaccines since in this context cellular CTL responses 
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correlate with improved survival 74. Some authors demonstrated that the progressive 
antigen release from polymeric nanoparticles elicits more potent cellular responses 
compared to other formulations that favor a burst antigen release, highlighting the 
importance of the kinetics of antigen release 75, 76. In this case, the most beneficial 
antigen attachment strategies would be those that enable a sustained release of the 
antigenic material.  
- The incorporation of multiple antigenic peptides to nanoparticles in order to reinforce the 
immunosurveillance role of the immune system 77. Since the tumor can evade the 
immune recognition by presenting a myriad of mutated versions of antigens, the 
administration of a variety of antigenic epitopes would increase the chances of the 
immune system for recognizing the tumor.   
- The co-administration of antigen and adjuvants to potentiate DC maturation 78. Both the 
loading of antigen and adjuvant on the same or separate nanocarriers have been reported 
to induce specific CTL responses in vivo 79, 80. The employment of particulate forms of 
antigen and adjuvants facilitates the targeting to the same intracellular compartment, 
which has been demonstrated to be crucial for obtaining efficient immune responses 81.  
 
Apart from the modulation of anti-tumor immunity, another immunotherapeutic strategy in 
which nanotechnology is making an important contribution is the regulation of the tumor 
microenvironment. For this purpose, several approaches have been investigated: 
- Suppression of the immunoinhibitory nature of the tumor microenvironment through the 
targeted silencing of some of the key inducers, such as the transcription factor STAT3 or 
the transforming growth factor β (TGFβ) 82, 83. This strategy increases the CD8+ T-cell 
infiltration rate into the tumor, resulting in improved outcomes.  
- Modulation of the activity or proliferation of tumor infiltrating immune cellular 
populations that potentiate the immunosuppressive nature of the tumor microenvironment 
by blocking CTL responses, such as tumor-associated macrophages (TAMs) or myeloid 
derived suppressor cells (MDSCs). Both populations can be selectively depleted through 
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the targeted release of nanoparticles loaded with cytotoxic drugs such as clodronate or 6-
thioguanine 84, 85. Alternatively, the M2 immunosuppressive phenotype of TAMs can be 
shifted towards a M1 pro-inflammatory profile in order to reverse the tumor supportive 
role of this cellular population. In this case, the intrinsic immunogenic properties of iron 
oxide nanoparticles can be exploited 68. 
 
Exciting advances are currently under development related to the application of biomaterials to 
immunotherapy 86. An innovative example is the de novo generation of synthetic lymphoid 
organs in vivo 87 or the in vitro generation of a thymus-resembling structure that acts as a 
platform to create large amounts of T lymphocytes in vitro for supporting anti-cancer 
immunotherapeutic approaches such as autologous cell transfers 88. Another impressive proposal 
is the design of nanomaterials-based artificial antigen presenting cells (APCs) that trigger T cell 
immune responses eliminating the need of autologous APCs manipulation ex vivo. In this case, 
biomaterials are loaded with the T cell growth factor IL-2, essential for the expansion and 
differentiation of T lymphocytes, and the anti-CD3 antibody, which activates T cells by 
clustering TCR-CD3 complexes on the T cell membrane 89.  
All in all, nanoparticle-based therapeutic strategies are providing encouraging results in the pre-
clinical stage. Nevertheless, several obstacles must be overcome in the near future before 
nanomaterial-enabled cancer immunotherapy is widely applicable in the clinic. For instance, 
more accurate animal models are required in order to predict the vaccine efficacy in humans and 
non-human primates. In the years to come, nanomedicine will greatly benefit from advances in 
oncoimmunology, which will provide a deeper understanding of immunoregulatory mechanisms, 
the tumor microenvironment contribution, the vaccine kinetics and the interaction between the 
immune system and biomaterials. From the nanomaterials point of view, safety issues must be 
clarified in order to avoid deleterious responses inherent to the materials themselves. The main 
toxicity concerns related to inorganic nanoparticles are related to the long-term persistence in the 
host of non-biodegradable particles, the size-dependent biodistribution, the surface charge and 
hydrophobicity of such materials. The safety-related requirements of a candidate vaccine may 
vary depending on its potential application.  The administration of nanomaterials-based vaccines 
is more likely to occur for the treatment of patients suffering from a potentially lethal disease 
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such as cancer, rather than as a prophylactic treatment for children. In the latter case, the safety 
standard is expected to be reasonably higher than in the former one, in which some adverse side-
effects might be tolerated. Ideally, nanoparticulate therapies should ensure high drug loading, a 
long stability in circulation and an easy scalability, which remains challenging 49. Importantly, 
manufacturing strategies must be defined in order to ensure a reproducible and controlled 
production of high-quality nanodevices with a reasonable cost both of the manufacturing process 
and the final product.  
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ES1. Synthesis and characterization of SPION and ZnSPION. 
Hydrophobic magnetite (Fe3O4) nanoparticles (SPION) were synthesized by the thermal 
decomposition method. The chemical reactants, iron(III) acetylacetonate (2 mmol), 
1,2‑ hexadecanediol (10 mmol), oleic acid (6 mmol), oleylamine (6 mmol) and benzyl ether (20 
mL), are mixed under a flow of nitrogen and heated for 210 °C for 2 h. Then the mixture is 
heated to reflux (300 °C) for 1 h. After cooling down to room temperature, ethanol (40 mL) is 
added to precipitate nanoparticles and they are separated by centrifugation (30 min, 3000 x g). 
The isolated pellet is then dissolved in hexane (10 mL) in the presence of oleic acid (0.05 mL) 
and oleylamine (0.05 mL). Centrifugation (10 min, 3803 x g) is applied to remove any 
undispersed residue. Ethanol (20 mL) is added and then centrifuged (10 min, 3803 x g). 
The hydrophobic zinc ferrite nanoparticles, (ZnxFe1-x)Fe2O4 (x<=0.4) (ZnSPION) were prepared 
by the thermal decomposition method by heating at 200°C a mixture of iron(III) acetylacetonate 
(4 mmol), hexadecanediol (25 mmol), oleic acid (15 mmol), hexadecylamine (15 mmol) and 
octyl ether for 1 h. During the second step of the reaction, diethylzinc (0.85 mmol) is added as a 
Zn source, and the temperature of the reaction is raised up to 300 °C for 1 h. Then the mixture is 
cooled down to room temperature, and ethanol (40 mL) is added to precipitate nanoparticles. For 
further purification, the pellet is centrifuged (10 min, 3803 x g) and left on air until complete 
evaporation. 
The synthesis of hydrophobic iron oxide nanoparticles was carried out by Dr. Macarena 
Cobaleda and Dr. Nina Gómez.  
The size of hydrophobic IONPs was determined by transmission electron microscopy (TEM) on 
a JEOL JEM-2011 electron microscope operating at 200kV. The samples were prepared by 
depositing a drop of IONPs onto a copper specimen grid coated with a holey carbon film 
(Electron Microscopy Sciences). Samples were prepared by dissolving 1 mg of nanoparticles in 
tetrahydrofuran (THF) to a final concentration of 0.1 mg/mL. At least 300 particles were 
measured using the Image J software to determine IONP size. 
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ES2. Synthesis and characterization of SPION and ZnSPION- filled micelles. 
The synthesis of the water soluble IONPs-filled micelles is based on the self-assembly of 
PEGylated phospholipids around the hydrophobic cores of IONPs.  
The synthesis of SPION filled micelles was carried out by dissolving DPPE-mPEG(2000) (2 mg) 
and SPION (1 mg) in chloroform (500 µL). The solvent was allowed to evaporate overnight in a 
3 mL round bottom flask at RT. Any remaining solvent was removed under vacuum for 1 h. The 
flask was placed in a water bath at 80 °C for 30 s, after which 1 mL of nanopure water was 
added. The solution was transferred to an Eppendorf tube and centrifuged at 9700 g for 5 min. 
The pellet was discarded and the supernatant was passed through a 0.45 µm filter. This solution 
was ultracentrifuged (369 000 x g, 1 h, 3 cycles) to remove the empty micelles. Finally the pellet 
was dissolved in 1 mL of nanopure water. 
For the synthesis of ZnSPION-filled micelles, different ratios of lipids and ZnSPION-to-lipid 
ratios were used: zinc ferrite nanoparticles (1 mg) and DPPE-mPEG(2000) (5 mg) for ZnSPION-
PEG or DOTAP (1 mg) and DPPE-mPEG(2000) (4 mg) for ZnSPION-DOTAP were dissolved 
in chloroform (500 µL). The rest of the protocol was followed as previously described. 
Fluorescent micelles were prepared following the same protocol described above, with only two 
modifications: lissamine rhodamine dipalmitoylphosphatidylethanolamine was added (5 % of 
total moles of lipids) to the chloroform solutions of PEGylated lipids and IONPs; and the whole 
protocol was carried out in the darkness to preserve the fluorescence of the dye. 
The hydrodynamic size of micelles and zeta potential in solution was measured with a NanoSizer 
(Malvern Nano-Zs, UK). Size measurements were carried out in disposable micro cuvettes (70 
µL, Brand), with samples diluted in water to a final iron concentration of 8 mM, while zeta-
potential measurements were acquired in clear disposable folded capillary cells (Malvern) with 
samples diluted in nanopure water with NaCl 0.09% V/V to a final concentration of 1 mM Fe. 
The selected voltage was 40 V. All the results are an average of 5 measurements matching 
quality criteria. 
TEM studies were conducted on a JEOL JEM-2011 electron microscope operating at 200 kV. 
The samples were prepared by depositing a drop of IONPs onto a copper specimen grid coated 
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with a holey carbon film (Electron Microscopy Sciences) after treating it to make it highly 
hydrophilic and allowing it to dry. 
XPS experiments were performed in a SPECS Sage HR 100 spectrometer with a 
non-monochromatic X-ray source (aluminum Kα line of 1486.6 eV energy and 350 W). The 
samples were placed perpendicular to the analyzer axis and calibrated using the 3d5/2 line of Ag 
with a full width at half maximum (FWHM) of 1.1 eV. The selected resolution for the spectra 
was 10 eV of Pass Energy and 0.15 eV/step. Measurements were made in an ultra high vacuum 
(UHV) chamber at a pressure below 8·10-8 mbar. XPS experiments and subsequent data analysis 
were carried out by Dr. Luis Yate, head of the surface analysis and fabrication platform of CIC 
biomaGUNE. 
The thermogravimetric analysis (TGA) was performed on a TGA/SDTA 851 Mettler Toledo 
thermogravimetric analyzer under nitrogen atmosphere at a heating rate of 10 K/min at the 
SGIker analytical facility of the University of the Basque Country (UPV/EHU; San Sebastián, 
Spain). 
Magnetic measurements were done using the Vibrating Sample Magnetometry (VSM) technique 
at the SGIker analytical facility of the University of the Basque Country (UPV/EHU; Leioa, 
Spain)). The hysteresis loops at RT, with very good low field accuracy (better than 1 x 10-5 T) 
were performed in a home‑ made VSM equipped with an electromagnet up to a maximum field 
of 1.8 T. Another VSM fitted to a Cryogenic Free 14 T magnet system (Cryogenic Ltd) was used 
for the measurements below RT from ‑ 8 T to +8 T. 
Attachment of Poly(I:C) and imiquimod. Lyophilized Poly(I:C) and imiquimod (Invivogen) were 
resuspended in endotoxin-free water to a final concentration of 1000 µg/mL and 500 µg/mL, 
respectively. Double-functionalized IONPs were developed through a two-step process. First, 
IONP-filled micelles were mixed with Poly(I:C) and the mixture was stirred overnight at 700 
rpm at room temperature. The excess of unbound Poly(I:C) was purified in three cycles (5 
minutes at 1475 x g) of ultrafiltration with NanoSep 100k (MWCO 100 kDa) centrifugal devices 
(Pall Life Sciences). Then, Poly(I:C)-IONP micelles were resuspended in an imiquimod solution, 
keeping the final volume constant (IONPs pICR). This mixture was stirred and purificated 
again exactly the same way as described above. The final pellet was resuspended in the same 
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initial volume of nanopure water or phosphate buffered saline (PBS) and stored at 4 °C. The 
same procedure with the opposite order of addition of TLR agonists was followed to develop 
IONPs RpIC.  
Attachment of ovalbumin. SPION-filled micelles for OVA attachment were formulated with 1 
mg of SPION, 2 mg of DPPE-mPEG(2000) and 2 mg of DPPE-cPEG(2000). For the chemical 
activation of carboxylic groups of PEGylated lipids of SPION-filled micelles, these were mixed 
with EDC/NHS in 1:25:25 molar ratio and stirred for 2 h at room temperature in MES buffer 10 
mM pH=5.0. The excess of EDC/NHS was removed by ultrafiltration with NanoSep 100k 
(MWCO 100 kDa) centrifugal devices (Pall Life Sciences) (1475 x g for 5 min, 3 cycles). The 
resulting activated SPION-micelles were resuspended in the initial volume and stirred overnight 
at room temperature with EndoGrade® endotoxin-free ovalbumin (Hyglos) in a final volume of 
300 µL of phosphate buffered saline (PBS). The unbound OVA was eliminated by ultrafiltration 
at 1475 x g for 5 min (3 cycles). The pellet was resuspended in the initial volume of PBS (10 
mM) and stored at 4 °C. 
ES3. Characterization of Poly(I:C)-imiquimod-IONP micelles. 
The Fe and Zn concentration in the samples were determined by ICP-OES analysis carried out 
by the SGIker analytical facility of the University of the Basque Country (UPV/EHU; Leioa, 
Spain). The samples were analyzed for Fe and Zn by ICP-OES using a Perkin Elmer Optima 
5300 DV, employing an RF forward power of 1400 W, with argon gas flows of 15, 0.2 and 0.75 
L/min for plasma, auxiliary and nebulizer flows, respectively. Using a peristaltic pump, sample 
solutions were taken up into a Gen Tip cross-Flow nebulizer and Scotts spray chamber at a rate 
of 1.50 mL/min. The instrument was operated in axial mode. The selected wavelengths (238.024, 
239.562, 259.939 nm) were analyzed in fully quant mode (three points per unit wavelength). A 
range of calibration standards were prepared using single element 1000 mg/L stock solutions 
(Fisher Scientific UK LTD) and a Merck multi element standard (ICP Multi element standard 
solution VI CertiPUR®) was employed as a reference standard. 
The quantification of bound imiquimod was performed by UV-vis spectroscopy, analyzing the 
absorption peak at 325 nm. The concentration of imiquimod was calculated by extrapolating that 
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absorbance to a calibration curve. Similarly, the Poly(I:C) content was determined by analyzing 
the absorption peak at 260 nm. UV-Vis absorption spectra were acquired using a NanoDrop ND 
1000 (version 3.5.2) Spectrophotometer (NanoDrop Technologies). 
The amount of OVA bound to SPION-OVA micelles was quantified using a bicinchoninic acid 
(BCA) protein assay reagent kit (Thermo scientific), after absorbance subtraction of the same 
concentration of parental SPION micelles. The absorbance measurements were performed in a 
96-well plate with a TECAN Genios Pro 96/384 microplate reader.  
Fluorescence experiments to assess the interaction of imiquimod with Poly(I:C) were conducted 
in a fluorometer Horiba by irradiating the samples with an excitation wavelength of 250 nm. 
The interaction between Poly(I:C) and imiquimod was also determined by circular dichroism 
(CD) measurements. The CD spectra were acquired between 180 and 350 nm on a Jasco J-815 
CD spectrometer fused with nitrogen gas. A fixed concentration of Poly(I:C) (50 μg/mL) was 
titrated with increasing concentrations of imiquimod until saturation was achieved. All the 
spectra measurements were carried out in a 1 mm path length cuvette. Results are the average of 
five spectra measured at room temperature. Baseline and smoothing corrections have been 
applied. 
ES4. Imaging studies. 
C57BL/6 female mice (6-8 weeks old) were s.c. challenged with 3x105 B16F10(OVA) tumor 
cells resuspended in 100 μL of PBS. Mycoplasma test (Lonza) was carried out prior to injection 
to ensure that cells were free of contamination. The tumors were left to settle and grow until the 
diameter reached around 7 - 12 mm for MR imaging acquisition. At the beginning of the 
experiments, mice were immunized with SPION and ZnSPION decorated with Poly(I:C) and 
imiquimod at a concentration of 6 or 11 mMFe. 100 μL of sample were s.c. injected in the tumor 
vicinity. Images were acquired at times prior injection, 24 h and 48h post injection (p.i.) to 
analyze accumulation of nanoparticles in the inguinal lymph nodes and tumor (Figure ES1). 
Animals were anesthetized prior to imaging using 3.5 % isofluorane and maintained at 1.5 – 2.5 
% isoflurane in 100 % O2 during the whole acquisition. Animals were placed in a mouse holder 
compatible with the MRI equipment and kept at a constant body temperature of 37 °C 
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throughout the study using a heated water blanket. Temperature and respiration rate was 
monitored with an MRI compatible animal monitoring system (SA Instruments Inc., New York, 
USA) with animals maintained at a respiration rate of 60 - 80 breaths per minute. Experiments 
were performed on a 70/30 Bruker Biospec system (Bruker Biospin GmbH, Ettlingen, Germany) 
using the BGA12-S mini imaging gradient and 40 mm inner diameter transmit/receive mouse 
body volumetric coil. Axial gradient echo experiments were performed with the following 
parameters: A respiration synchronized (TR = one respiration cycle) FLASH sequence, TE = 3 
ms, FOV = 28 mm x 28 mm, Matrix = 256 x 256, Slice Thickness = 0.75 mm , N Slices= 32 and 
2 averages. Axial T2 maps were acquired using the following parameters: A respiration 
synchronized (TR = 6 respiration cycles) Multi Slice Multi Echo (MSME) sequence, TE = 8, 16, 
24, 32, 40, 48, 56, 64 ms; FOV = 28 mm x 28 mm, Matrix = 128 x 128, Slice Thickness = 0.75 
mm, N Slices= 9 and 2 averages. The images were fitted into Levenberg-Margardt method to 
calculate T2 values using Bruker's Paravision 5.1 software. These experiments were carried out 
by Dr. Daniel Padro, head of the NMR platform of CIC biomaGUNE. 
Figure ES1. MR images of a B16F10(OVA) tumor bearing mice. Inguinal lymph nodes (dashed 
circles) and tumor (solid circle) are indicated on the images. Transverse (a) and longitudinal (b, 
c) sections are shown. Right (b) and left (c) inguinal lymph nodes are depicted separately in the
longitudinal axis. 
Relaxivity measurements were carried out at 37 ⁰C on a Bruker Minispec mq60 instrument 
operating at 1.47 T. T1 and T2 values were measured for each sample at different Fe 
concentrations using inversion-recovery and CPMG methods respectively. The relaxivity values, 
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r1 and r2, were calculated through linear least squares fitting of 1/relaxation time (s
-1) versus the 
iron concentration ([Fe] mM). The measurements were carried out in collaboration with Dr. Nina 
Gómez. 
The MRI phantom experiments were carried out on a Bruker Biospec 11.7 T with a 9 cm 
gradient capable of delivering 740 mT/m using a 40 mm volume coil. T2 maps were acquired by 
using Bruker's MSME (Multi slice Spin echo) sequence. The echo time (TE) values were varied 
in 128 steps ranging from 10 ms to 1280 ms and a repetition time (TR) of 15 s. T1 maps were 
obtained by using a spin echo sequence. Images were acquired at ten different TR values 150, 
500, 1000, 1500, 2200, 3000, 4000, 5200, 7.600, 17500 ms). All data were acquired with: 256 x 
256 points and a Field of View of 3 cm x 3 cm, slice thickness of 1.5 mm, no gap between slices 
and one average. T2 weighted images correspond to TE = 36 ms and TR = 15 s. The T1 and T2 
map images were calculated using the Bruker's Paravision 5.1 software via the 
Levenberg‑ Margardt method. The relaxivity values, r1 and r2, were calculated through linear 
least squares fitting of 1/relaxation time (s‑ 1) versus the iron concentration ([Fe] mM). This 
experiment was carried out by Dr. Nina Gómez in collaboration with the NMR platform of CIC 
biomaGUNE.  
SPECT/CT studies. 
67Ga was purchased as citrate solution from Molypharma (Spain) (specific activity =1.4 
TBq/μmol), and converted into 67GaCl3. Briefly, the gallium citrate solution was passed through 
a light silica column cartridge (Sep-Pak, Waters) to selectively retain the radiometal. The 
cartridge was washed with ultrapure water (10 mL) and 67Ga was finally eluted with HCl 0.1 M 
solution. The eluate was collected in different 100 μL fractions, and only those containing the 
maximum activity concentration were used in subsequent labeling experiments. The eluted 67Ga 
chloride solution (100 μL, c.a. 110 MBq) was then mixed with 100 μL of IONP micelle solution 
and diluted up to final volume of 400 μL in acetate buffer (pH = 3.8 ± 0.1). After incubation at 
70 °C during 30 min, the reaction crude was cooled down to room temperature and the labeled 
NPs were separated via centrifugal filtration (6708 x g for 10 min for SPION pIC->R; 3354 x g 
for 10 min for ZnSPION pIC->R) using AmiconUltracel 100k (MWCO 100 kDa) centrifugal 
devices (Merck), and washed twice with phosphate buffered solution. The retentate was 
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recovered from the filter by the addition of 10 mM PBS (100 μL). The total radioactivity in the 
filtrates and retentates were measured in a CRC-25R dose calibrator (Capintec, USA) in order to 
determine the incorporation efficiency. For stability studies, one batch of 67Ga-IONP micelles 
was fractioned in different aliquots, which were incubated in the presence of DOTA chelating 
agent (c.a. 106 moles of DOTA per mole of nanoparticle) at 37 °C. At different timepoints, the 
samples were filtered in order to separate the NPs from the 67Ga complexed to DOTA, and 
radioactivity in the retentate and in the filtrate was measured with the CRC-25R dose calibrator 
(Capintec, USA). The dissociation of 67Ga (expressed in percentage) from the radiolabeled 
micelles at each time point was calculated as the ratio between the amount of radioactivity in the 
filter and the starting amount of radioactivity. 
C57BL/6 female mice (6-8 weeks old) were s.c. challenged with 3x105 B16F10(OVA) tumor 
cells resuspended in 100 μL of PBS. Mycoplasma test (Lonza) was carried out prior to injection 
to ensure that cells were free of contamination. The tumors were left to settle and grow until the 
diameter reached around 7 - 12 mm. Then, mice were immunized with 67Ga labeled SPION and 
ZnSPION filled micelles decorated with Poly(I:C) and imiquimod dissolved in PBS to a 
concentration of 1.21 mMFe. 50 μL of sample/mouse were s.c. injected in the tumor vicinity. 
Animals were anesthetized prior to imaging using 3.5 % isofluorane and maintained at 1.5 – 2.5 
% isoflurane in 100 % O2 during the whole acquisition. Whole-body SPECT/CT scans were 
acquired at 3 and 24 h postinjection (p.i.). With the full ring detector, 360° of data were acquired 
by rotating the collimator 45° (45 steps, 1°/step). Data were collected in an energy acquisition 
window from 125−150 keV to 84−102 keV and acquisition times from 60 min (80 s/step) to 45 
min (60 s/step). At the end of the scanning procedure, the mice were culled by cervical 
dislocation and organs of interest removed. Analysis of the injected dose percentage per organ 
was performed by measuring their activity with a WIZARD22470 Automatic Gamma Counter 
(PerkinElmer). These experiments were carried out by Dr. Ane Ruiz de Angulo in collaboration 
with the radiochemistry platform of CIC biomaGUNE. 
ES5. Cytotoxicity studies. 
J774.A1 murine macrophage cell line was purchased from the ATCC and cultured in DMEM 
(Gibco, Life Technologies) supplemented with 10 % FBS (Gibco, Life Technologies), 1 % L-
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glutamine (Gibco, Life Technologies) and 1% penicillin-streptomycin (Sigma Aldrich), and 
maintained in a humid atmosphere at 37 °C and 5 % CO2. To assess cell viability at 24 h, cells 
were seeded at 2.5 x 104 cells/well (100 µL per well) in flat bottom 96-well plates and allowed to 
adhere overnight.  
The B16F10(OVA) murine skin melanoma cell line stably transfected with a plasmid responsible 
of the expression of ovalbumin was kindly gifted by the group of Dr. Pablo Sarobe (Center of 
Applied Medical Research, CIMA, Pamplona, Spain). These cells were cultured in RPMI 
(Lonza) supplemented with 10 % FBS, 1 % L-glutamine and 1% penicillin-streptomycin, and 
maintained in a humid atmosphere at 37 °C and 5 % CO2. To assess cell viability at 24, 48 and 
72 h, cells were seeded at 7 x 103, 2.5 x 103 and 1.5 x 103 cells/well (100 µL/well), respectively, 
in flat bottom 96-well plates and allowed to adhere overnight. 
Media was removed from each well prior to adding 100 µL of each sample, properly diluted in 
cell culture media, per well in triplicate. After incubation, the supernatants were removed and 
frozen for further cytokine analysis. To determine cell viability, 100 µL/well of MTT reagent 
(Roche) diluted in media to a final concentration of 0.25 mg/mL was added after removal of the 
supernatant. After a 1 h-incubation at 37 °C, the reagent was removed and 200 µL/well of 
DMSO were added to solubilize formazan crystals. Finally the optical density of the samples was 
measured in a TECAN Genios Pro 96/384 microplate reader at 550 nm and data was represented 
as the percentage of cell survival compared to control wells.  
ES6. In vitro co-culture assays. 
In order to determine the production of the M1 macrophage phenotype marker TNFα, the 
J774A.1 macrophage cell line was co-cultured with the B16F10(OVA) melanoma cell line in 
dual chamber transwell systems with 8 µm-sized microporous polycarbonate membranes 
(Corning). 5x104 J774A.1 cells/well were seeded onto the upper chambers of the transwell 
plates, and 7x103 B16F10(OVA) cells/well were placed into the bottom wells. Co-cultures were 
incubated for 24 h in a humid atmosphere at 37 °C and 5 % CO2 with samples conveniently 
diluted in DMEM supplemented with 10 % FBS, 1 % L-glutamine and 1% penicillin-
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streptomycin. Cell culture supernatants were collected and stored at -20 °C for further cytokine 
content analysis by ELISA.  
ES7. Quantification of cytokines and antibody production by ELISA. 
IL-6, IL-12, IL-10 and TNFα were measured in cell supernatants using sandwich ELISA 
following the manufacturer’s instructions (murine IL-6 mini EDK ELISA kit, R&D Systems; 
murine IL-12 and TNFα mini EDK ELISA kits, Peprotech; mouse IL-10 ELISA MAX standard 
set, Biolegend). A 4-parameter sigmoidal (logistic) standard curve was used to quantify 
cytokines (GraphPad Prism 5 software). Results are expressed as mean ± SEM in pg/mL or 
ng/mL.  
Anti-OVA IgG1, IgG2c and IgGt antibodies were measured in blood serum using indirect 
ELISA. Flat bottom 96 well EIA/RIA plates (Corning) were covered with 50 µL/well of OVA 
diluted in PBS to a final concentration of 0.04 mg/mL. The samples of blood serum were 
obtained from immunized mice by facial vein puncture and centrifuged at 13000 x g for 5 min to 
remove the cellular content of the blood. After the samples incubation, the concentrations of 
antigen-specific antibodies were determined with HRP-conjugated anti-mouse IgG1, IgG2c and 
IgGt antibodies (BioRad) diluted 1:4000, 1:10000 and 1:500 in PBS, respectively. The results 
were expressed as the log10 value of the reciprocal of the endpoint dilution which gave an optical 
density (O.D.) of 0.2 or above, after the subtraction of the background levels.  
In both ELISA types, the measurement of each sample was conducted in duplicate. Absorbance 
measurements were carried out in a TECAN Genios Pro 96/384 microplate reader at 450-550 
nm. 
ES8. Localization of intracellular nanoparticles by confocal microscopy. 
The murine macrophage cell line J744.A1 was seeded in poly-lysine-coated 35 mm glass bottom 
dishes (MatTek) and grown at 37 ºC and 5% CO2 in 2mL of DMEM medium supplemented with 
10% bovine fetal serum, 2 mM L-glutamine, and 50 U/mL penicillin/streptomycin. Then, cells 
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were incubated for 1h at 37 ºC and 5 % CO2 in media containing rhodamine-labeled ZnSPION-
filled micelles (25 nM NP) with/without DOTAP decorated with Poly(I:C) and imiquimod, 1 µM 
LysoTracker Green DND-26 (Invitrogen) and 3 drops of NucRed® Live 647 ReadyProbes® 
Reagent (Life Technologies). Imaging was performed on a Zeiss LSM 510 META confocal 
microscope equipped with 63X magnification oil lens. Fluorescence images were taken in 
sequential mode at the excitation wavelengths of 488 nm, 561 nm and 633 nm for LysoTracker 
Green DND-26, rhodamine B or NucRed® Live 647 ReadyProbes® Reagent, respectively. The 
thickness of each optical slice was set at 3 µm for each color channel. Transmitted light images 
were also acquired. Image analysis was performed with the Zeiss LSM Image Browser. These 
experiments were carried out by Dr. Blanca Arnáiz.  
ES9. BMDC maturation assay. 
Balb/c mice (6-12 weeks old) were sacrificed by cervical dislocation and intact femurs were 
removed aseptically. Femurs were placed in ethanol for 2 min and washed in cold PBS. Bone 
marrow was flushed into cold PBS using a syringe and cellular clusters were disaggregated to 
obtain a homogeneous cell suspension. Erythrocytes were lysed with BD Pharm Lyse lysing 
buffer (BD Biosciences) and cells counted. 2 x 106 cells/dish were plated in bacterial grade Petri 
dishes, in 10 mL/dish of RPMI supplemented with penicillin/streptomycin (100 µg/mL), L-
glutamine (2 mM), heat-inactivated FBS (10%) and GM-CSF (Peprotech, 20 ng/mL). On day 3, 
10 mL of complete RPMI containing GM-CSF (20 ng/mL) was added to each Petri dish. On day 
6, 10 mL of media was carefully removed and replaced with 10 mL/dish of fresh RPMI 
supplemented with GM-CSF (10 ng/mL). On day 8, BMDCs were removed by carefully 
dislodging semi-adherent cells using light pipetting to avoid activating the cells.  
For cytotoxicity assays, cells were counted and resuspended in RPMI at a final concentration of 
2 x 105 cells/well in 96-well tissue culture plates (100 µL/well). Samples to be tested (100 
µL/well, appropriately diluted in RPMI) were added to the DC containing wells and incubated 
for 24 h in a humid atmosphere at 37 °C and 5 % CO2, following which supernatants were 
recovered and frozen for later testing of cytokines. The cell viability of BMDCs was analysed 
using the MTT assay, following the same procedure described above. 
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For maturation assays, BMDCs were counted and resuspended in RPMI (10 % FBS, 1 % L-
glutamine, 1 % penicillin-streptomycin). They were seeded in a 96-well tissue culture plate at 2 x 
105 cells/well (100 µL/well). Samples to be tested (100 µL/well, appropriately diluted in RPMI) 
were added to the DC containing wells and incubated for 24 h in a humid atmosphere at 37 °C 
and 5 % CO2, after which they were immunostained to analyze the expression profile of MHC-II 
and the maturation markers CD80, CD86 and CCR7.  
To carry out the immunostaining procedure, BMDCs were firstly washed with PBS. In order to 
avoid non-specific cell staining, Fc receptors were blocked by incubating the cells with rat 
IgG2bk anti-mouse CD16/CD32 antibody (BD Biosciences) for 10 min at 4 °C. CCR7+ cells 
were stained with BV421-rat IgG2ak anti-mouse CD197 (Biolegend) for 15 min at 37 °C. A 
BV421-rat IgG2ak isotype control antibody was used to establish the background level of non-
specific fluorescence associated with cells after being stained with fluorochrome-associated 
antibodies. The next step consisted on staining cells with antibodies that define DC phenotype 
(APC-hamster IgG1λ2 anti-mouse CD11c and PerCP-Cy5.5-rat IgG2bk anti-mouse I-A/I-E 
antibodies, Biolegend) and maturation marker antibodies (FITC-dog IgG anti-mouse CD80 and 
PE-rat IgG2ak anti-mouse CD86 antibodies, Biolegend). The corresponding isotypes were 
acquired using FITC-armenian hamster IgG1 isotype control and PE-mouse IgG1 isotype control 
antibodies (Biolegend). This step was carried out at 4 °C for 15 min. Finally, cells were washed 
with PBS and resuspended in 200 µL of FACS buffer to be analyzed by flow cytometry using a 
FACS Canto II flow cytometer. The maturation markers expression was analyzed in the final 
gated DC population (cd11c+ MHC-II+). Isotype controls were included in each assay and are not 
included in the figures for clarity purposes. The gating strategy is detailed in Figure ES2. 
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Figure ES2. Gating strategy followed in BMCD maturation assays. The expression of 
maturation markers CD80, CD86 and CCR7 was analyzed in a population of dendritic cells 
phenotypically defined as cd11c+ MHC-II+. 
ES10. Animals. 
Animals were cared for and handled in compliance with the Guidelines for Accommodation and 
Care of Animals (European Convention for the Protection of Vertebrate Animals Used for 
Experimental and Other Scientific Purposes) and internal guidelines, and all the experimental 
procedures were approved by the appropriate local authorities. All animals were housed in 
ventilated cages and fed on a standard diet ad libitum. 
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ES11. Splenocytes and lymphocytes primary culture preparation. 
For the analysis of innate and adaptive immune responses induced in vivo after immunization, 
spleens and draining lymph nodes (dLNs) were removed and processed for further analysis ex 
vivo. Briefly, organs were perfused with tissue dissociating mix (3 mL of collagenase/DNase I 
diluted in RPMI media), cutted into small pieces (spleen) and incubated for 30 min at 37 °C in a 
sterile Petri dish. The reaction was stopped with 500 mM EDTA and organs were smashed with 
the plunger of a syringe. Red blood cells lysis was performed in those cell suspensions derived 
from spleens, by adding 1 mL of BD Pharm Lyse erythrocytes lysing buffer (BD Biosciences) for 
1 min and rapidly quenched with 10 mL of cold PBS. The resulting cell suspensions were 
recollected into 15 mL tubes, washed twice with cold PBS and resuspended in complete RPMI, 
ready for the subsequent studies. 
ES12. Assessing innate immune responses in vivo. 
C57BL/6J mice (6-8 weeks old) were injected intra-hook in the inner side of one of the back feet 
with the corresponding formulations diluted in PBS (40 µL/mouse). Mice were immunized once 
with 2.8 µg Poly(I:C)/mouse, 0.9 µg imiquimod/mouse and 4.8 µg ZnSPION/mouse (ZnSPION 
pIC->R) or 5 µg Poly(I:C)/mouse, 1 µg imiquimod/mouse and 6.4 µg ZnSPION/mouse 
(ZnSPION-DOTAP pIC->R). An additional control with free TLR agonists at high concentration 
was also included in order to compare the effect of the dose on the induction of innate immune 
responses (12 μg Poly(I:C)/mouse and 3 μg imiquimod/mouse). 24 h after immunization, mice 
were sacrificed by cervical dislocation and spleen and inguinal and popliteal lymph nodes were 
extracted and processed as described before for further analysis of the maturation of DC and NK 
cellular populations. Briefly, 1x106 cells/well diluted in RPMI were seeded in a 96-well plate and 
divided into two different staining panels. For the DC maturation analysis, cells were stained and 
gated as described in the in vitro BMDC maturation assays (Figure ES3), analyzing this time an 
additional maturation marker, CD40 (PE/Cy7-rat IgG2ak anti-mouse CD40, and its 
corresponding isotype control antibody PE/Cy7-rat IgG2ak, Biolegend).  
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Figure ES3. Gating strategy followed in the innate immune response assays. The expression of 
the maturation markers CD80, CD86, CD40 and CCR7 was analyzed in a population of 
dendritic cells phenotypically defined as cd11c+ MHC-II+. 
In the case of the NK staining panel, cells were stained with BV421-rat IgG2bk anti-mouse CD3, 
PE-rat IgG2ak anti-mouse NKp46 and APC-armenian hamster IgG anti-mouse CD69 antibodies, 
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and the corresponding isotype control antibody APC-armenian hamster IgG (Biolegend). The 
NK population was defined as CD3- Nkp46+, and CD69 expression was analyzed into this gated 
population (Figure ES4). 
Figure ES4. Gating strategy followed in innate immune response assays. The expression of 
CD69 was analyzed in a population of natural killer cells phenotypically defined as CD3- 
Nkp46+. 
ES13. Assessing adaptive immune responses in vivo. 
C57BL/6J mice (6-8 weeks old) were injected subcutaneously in both flanks (100 μL/flank). 
Mice were immunized twice with a two weeks time lapse with 5 µg OVA/mouse, 3.8 µg 
Poly(I:C)/mouse, 0.5 µg imiquimod/mouse and 12.1 µg/mouse ZnSPION. Blood extractions 
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were carried out by facial vein puncture at different timepoints (pre- and post- injection), and 
serum was analyzed for the presence of anti-OVA IgG antibodies by standard indirect ELISA. 
Three weeks after the last immunization, mice were sacrificed by cervical dislocation and 
splenocytes and lymphocytes from inguinal lymph nodes and spleen were extracted as described 
before. SIINFEKL-specific CD8+ T cells were analyzed in blood, spleen and lymph nodes. 1x106 
cells were stained with FITC-rat IgG2ak anti-mouse CD8 and APC-rat IgG2bk anti-mouse CD3 
antibodies (Biolegend) to define the CD3+ CD8+ T cell population, specifically excluding CD3+ 
CD4+ cells. The percentage of SIINFEKL-specific cells was analyzed in the CD3+ CD8+ double 
positive population (Figure ES5), using PE-labeled anti-H-2kb-OVA257-264 (Immudex). Data are 
presented as an average of 5 mice per group of immunization, analyzed individually. 
Figure ES5. Gating strategy followed in the adaptive immune response assays. The percentage 
of SIINFEKL-specific CD8+ T cells in the blood, spleen and inguinal lymph nodes of immunized 
mice was analyzed in a population of CD3+ CD8+ T lymphocytes. 
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ES14. Tumor challenge in vivo functional studies. 
C57BL/6J mice (6-8 weeks old) were immunized via subcutaneous injection on the flanks (100 
μL/flank), before (prophylactic setting) or after (therapeutic setting) challenge with 3x105 
B16F10(OVA) tumor cells resuspended in 100 μL of PBS. Mycoplasma test (Lonza) was carried 
out prior to injection to ensure that cells were free of contamination. 
In the prophylactic approach, male mice were immunized twice with a two weeks interval 
between both injections with 5 μg/mouse of OVA, 45.7 μg/mouse of SPION, 3.5 μg/mouse of 
Poly(I:C), 1.3 μg/mouse of imiquimod  and 6.1 μg/mouse of ZnSPION (ZnSPION pIC-R) or 
with 5 μg/mouse of OVA, 45.7 μg of SPION, 10 μg/mouse of Poly(I:C), 2.3 μg/mouse of 
imiquimod and 12 μg of ZnSPION-DOTAP (ZnSPION-DOTAP pIC-R). Tumor cells were 
implanted one week after the last immunization. Blood extraction was carried out weekly to 
analyze the frequency of SIINFEKL-specific CD8+ T cells, following the same procedure 
described for the adaptive immune response assays. Tumors were measured every two to three 
days with a digital caliper until day 31 after tumor inoculation, and volumes (V) were calculated 
as V (mm3) = [(short diameter)2 x (long diameter)]/2. Mice were considered tumor-free until 
dermal lesions were visible or palpable. For survival rate evaluation, mice were kept until 
sacrifice was necessary once the tumor reached a diameter of ≥ 15 mm or when tumor necrosis 
or ulceration signs appeared, according to legal requirements. In the case of mice surviving with 
no tumor or no signs of debilitating sickness, the experiment was ended 57 days after tumor 
inoculation.  
In the case of prophylactic assays carried out in female mice, they were immunized twice with a 
two weeks interval between both injections with 5 μg/mouse of OVA, 56.6 μg/mouse of SPION, 
8 μg/mouse of Poly(I:C), 2.5 μg/mouse of imiquimod  and 10.1 μg/mouse of ZnSPION 
(ZnSPION pIC-R) or with 5 μg/mouse of OVA, 56.6 μg of SPION, 12 μg/mouse of Poly(I:C), 
3.6 μg/mouse of imiquimod and 20.9 μg of SPION (SPION pIC-R). 63 days after the first tumor 
challenge, healthy mice were s.c. re-challenged with 3x105 B16F10(OVA) cells. As a control, a 
group of non-inmunized mice of the same sex and age were challenged with tumor cells in 
parallel. Tumor volume and survival rates measurements were carried out as described above. 
Survivor mice were sacrificed 108 days after the first tumor inoculation and the spleen and 
inguinal lymph nodes were extracted to analyze the immunological memory response developed. 
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Splenocytes and lymphocytes primary cell cultures were established as described above and 
divided into two groups for the characterization of the magnitude and quality of the memory 
response. In the first case, 1x106 cells were stained with PE/Cy7-rat IgG2ak anti-mouse CD8 and 
BV421-rat IgG2bk anti-mouse CD3 antibodies (Biolegend) to define the CD3+ CD8+ T cell 
population. The T central memory population (Tcm) is defined as CD62L+CD44+ while the T 
effector memory population (Tem) is CD62L-CD44+. The percentage of SIINFEKL-specific 
cells was analyzed (Figure ES6) in both populations (Tem and Tcm), using PE-labeled anti-H-
2kb-OVA257-264 (Immudex). Data are presented as an average of all the survivor mice in each 
group of immunization, analyzed individually. In order to assess the quality of the memory 
response, the production of the key intracellular cytokines TNFα, IFNγ and the degranulation 
marker CD107a was measured (Figure ES7) by intracellular FACS (icFACS). In this case, 
1x106 cells were stained with FITC-rat IgG2ak anti-mouse CD8 and BV421-rat IgG2bk anti-
mouse CD3 antibodies (Biolegend) to define the CD3+ CD8+ T cell population. TNFα, IFNγ and 
CD107a were stained with PE/Cy7-rat IgG1k anti-mouse TNFα, APC-rat IgG1k anti-mouse 
IFNγ and PE-rat IgG1ak anti-mouse CD107a (LAMP-1) (Biolegend), respectively. 
The in vivo synergistic immunostimulatory activity of the combined TLR agonists Poly(I:C) and 
imiquimod was demonstrated in female mice following the same procedure described for the 
prophylactic immunization assays. In this case, mice were immunized twice with 5 µg/mouse of 
OVA, 4 µg/mouse of Poly(I:C) and 2 µg/mouse of imiquimod, either individually or in 
combination. Tumor volume and survival rates measurements were monitored as described 
above for 48 days. 
In the therapeutic approach, female mice were immunized three times on days 4, 7 and 11 after 
tumor implantation with 5 μg/mouse of OVA, 27.1 μg/mouse of SPION, 8 μg/mouse of 
Poly(I:C), 2.3 μg/mouse of imiquimod and 10.1 μg/mouse of ZnSPION (ZnSPION pIC-R) or 
with 5 μg/mouse of OVA, 12 μg/mouse of Poly(I:C), 2.4 μg/mouse of imiquimod and 17.1 
μg/mouse of ZnSPION-DOTAP (ZnSPION-DOTAP pIC-R). For tumor volume measurements 
and survival rate assessment, we proceeded as described in the prophylactic setting. 
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Figure ES6. Gating strategy followed for the analysis of the magnitude of the immunological 
memory response generated at the end of the prophylactic immunization assay. The size of the T 
central (Tcm; CD62L+CD44+) and T effector (Tem; CD62L-CD44+) memory populations was 
determined in a population of CD3+ CD8+ T lymphocytes. The percentage of SIINFEKL-specific 
T-cells in the spleen and inguinal lymph nodes of immunized mice was analyzed in the 
population of CD3+ CD8+ Tem lymphocytes. 
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Figure ES7. Gating strategy followed for the analysis of the quality of the immunological 
memory response generated at the end of the prophylactic immunization assay. The intracellular 
production of the key cytokines TNFα, IFNγ and the degranulation marker CD107a was 
analyzed by intracellular FACS in the population of CD3+ CD8+ T lymphocytes. 
ES15. In vivo prophylactic immunization assays with modified B16F10(OVA) cell lines. 
Modified B16F10(OVA) with knock-down expression of PD-L1 (B16F10(OVA) C-C PD-L1) 
were obtained as result of a collaboration with the group of Dr. David Escors from 
Navarrabiomed (Pamplona, Spain). Briefly, lentiviral particles for silencing the expression of 
PD-L1 were produced in 293T cells. Cell culture supernatants were harvested, filtered through 
0.45 µm filter and ultracentrifuged for lentivectors purification. Lentiviral particles were titrated 
and used to transduce B16F10(OVA) cells. Knockdown cells were selected by antibiotic 
pressure with increasing concentrations of puromycin.  
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Similarly to the prophylactic immunization assays described above, C57BL/6J female mice (6-8 
weeks old) were immunized via subcutaneous injection on the flanks (100 μL/flank), before a 
tumor challenge with 3x105 B16F10(OVA) C-C PD-L1 cells resuspended in 100 μL of PBS. 
Mycoplasma test (Lonza) was carried out prior to injection to ensure that cells were free of 
contamination. 
Mice were immunized twice with a two weeks interval between both injections with 5 μg/mouse 
of OVA, 56.6 μg/mouse of SPION, 8 μg/mouse of Poly(I:C), 1.1 μg/mouse of imiquimod  and 
8.9 μg/mouse of ZnSPION (ZnSPION-DOTAP pIC-R). Tumor cells were implanted one week 
after the last immunization. 35 days after the first tumor inoculation, a contralateral tumor re-
challenge with 1.5 x 106 B16F10(OVA) C-C PD-L1 cells/mouse was carried out. Tumor volume 
and survival rates measurements were carried out as usual for 108 days.  
